Drug Profile
Androstenedione intranasal - Mattern
Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Mattern Pharmaceuticals
- Class Anxiolytics; Hormones
- Mechanism of Action Androgen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Polycystic ovary syndrome; Traumatic stress disorders
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Polycystic ovary syndrome in Switzerland (Intranasal) prior to September 2023 (Mattern Pharmaceuticals pipeline, September 2023)
- 05 Sep 2023 Discontinued - Preclinical for Traumatic stress disorders in Switzerland (Intranasal) prior to September 2023 (Mattern Pharmaceuticals pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Polycystic-ovary-syndrome in Switzerland (Intranasal, Gel)